Health Care - Biotech
Visional Inc had previously assumed a substantial slowing in BizReach sales growth over the FY as pent-up hiring demand after the COVID-19 state of emergency gradually petered out. In reality, whilst there was a small degree of quarterly deceleration, the rate of growth remained above plan and Visional ultimately concluded COVID-19 & demographic pressures had caused a structural shift in the recruitment market, with employers remaining increasingly likely to consider lateral hiring. On 38x FY 7/23 earnings, following a -19% decline from its Dec 2021 peak, Storm believe Visional’s long-term growth prospects have improved significantly but have not yet been discounted, so keep the 'Positive' rating.
Edition: 145
- 30 September, 2022